

Xianjun Yu

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/2278819/xianjun-yu-publications-by-year.pdf>

Version: 2024-04-23

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

308
papers

7,129
citations

44
h-index

69
g-index

324
ext. papers

10,236
ext. citations

6.8
avg, IF

6.12
L-index

#	Paper	IF	Citations
308	Pevedistat Suppresses Pancreatic Cancer Growth Inactivation of the Neddylation Pathway.. <i>Frontiers in Oncology</i> , 2022 , 12, 822039	5.3	0
307	SIGLEC15 amplifies immunosuppressive properties of tumor-associated macrophages in pancreatic cancer.. <i>Cancer Letters</i> , 2022 , 530, 142-142	9.9	3
306	Inhibition of SET domain-containing (lysine methyltransferase) 7 alleviates cognitive impairment through suppressing the activation of NOD-like receptor protein 3 inflammasome in isoflurane-induced aged mice.. <i>Human and Experimental Toxicology</i> , 2022 , 41, 9603271211061497	3.4	1
305	TGF- β -induced RAP2 regulates invasion in pancreatic cancer.. <i>Acta Biochimica Et Biophysica Sinica</i> , 2022 , 54, 361-369	2.8	0
304	The Role of PDGFRA in Predicting Oncological and Immune Characteristics in Pancreatic Ductal Adenocarcinoma.. <i>Journal of Oncology</i> , 2022 , 2022, 4148805	4.5	
303	The optimal duration of capecitabine plus temozolomide in patients with well-differentiated pancreatic NETs with or without maintenance therapy.. <i>Journal of Neuroendocrinology</i> , 2022 , e13112	3.8	0
302	Laparoscopic versus open pancreaticoduodenectomy for pancreatic ductal adenocarcinoma: study protocol for a multicentre randomised controlled trial.. <i>BMJ Open</i> , 2022 , 12, e057128	3	0
301	The Relationship of Redox With Hallmarks of Cancer: The Importance of Homeostasis and Context.. <i>Frontiers in Oncology</i> , 2022 , 12, 862743	5.3	2
300	Hypoxia-reprogrammed regulatory group 2 innate lymphoid cells promote immunosuppression in pancreatic cancer.. <i>EBioMedicine</i> , 2022 , 79, 104016	8.8	1
299	Value of lymphadenectomy in patients with surgically resected pancreatic neuroendocrine tumors.. <i>BMC Surgery</i> , 2022 , 22, 160	2.3	1
298	Health-related quality of life in patients with advanced well-differentiated pancreatic and extrapancreatic neuroendocrine tumors treated with surufatinib versus placebo: Results from two randomized, double-blind, phase III trials (SANET-p and SANET-ep).. <i>European Journal of Cancer</i> , 2022 , 163, 1-9	7.5	0
297	Comments on "Importance of Normalization of CA19-9 Levels After Neoadjuvant Therapy in Patients With Localized Pancreatic Cancer". <i>Annals of Surgery</i> , 2021 , 274, e800-e801	7.8	
296	Exosomes derived from immunogenically dying tumor cells as a versatile tool for vaccination against pancreatic cancer.. <i>Biomaterials</i> , 2021 , 280, 121306	15.6	3
295	Ferroptosis: At the Crossroad of Gemcitabine Resistance and Tumorigenesis in Pancreatic Cancer. <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6.3	5
294	Crosstalk between cancer-associated fibroblasts and immune cells in the tumor microenvironment: new findings and future perspectives. <i>Molecular Cancer</i> , 2021 , 20, 131	42.1	59
293	Patterns and predictors of pancreatic neuroendocrine tumor prognosis: Are no two leaves alike?. <i>Critical Reviews in Oncology/Hematology</i> , 2021 , 167, 103493	7	1
292	A Ki-67 Index to Predict Treatment Response to the Capecitabine/Temozolomide Regimen in Neuroendocrine Neoplasms: A Retrospective Multicenter Study. <i>Neuroendocrinology</i> , 2021 , 111, 752-763 ^{5.6}		4

291	The Chinese guidelines for the diagnosis and treatment of pancreatic neuroendocrine neoplasms (2020). <i>Journal of Pancreatology</i> , 2021 , 4, 1-17	1.9	3
290	Deciphering the Prognostic Implications of the Components and Signatures in the Immune Microenvironment of Pancreatic Ductal Adenocarcinoma. <i>Frontiers in Immunology</i> , 2021 , 12, 648917	8.4	11
289	Emerging roles of the solute carrier family in pancreatic cancer. <i>Clinical and Translational Medicine</i> , 2021 , 11, e356	5.7	6
288	From the Immune Profile to the Immunoscore: Signatures for Improving Postsurgical Prognostic Prediction of Pancreatic Neuroendocrine Tumors. <i>Frontiers in Immunology</i> , 2021 , 12, 654660	8.4	2
287	Role of tumor mutation burden-related signatures in the prognosis and immune microenvironment of pancreatic ductal adenocarcinoma. <i>Cancer Cell International</i> , 2021 , 21, 196	6.4	5
286	Development and multicenter validation of a nomogram for preoperative prediction of lymph node positivity in pancreatic cancer (NeoPangram). <i>Hepatobiliary and Pancreatic Diseases International</i> , 2021 , 20, 163-172	2.1	2
285	Identification of the Roles of a Stemness Index Based on mRNA Expression in the Prognosis and Metabolic Reprogramming of Pancreatic Ductal Adenocarcinoma. <i>Frontiers in Oncology</i> , 2021 , 11, 643465	5.3	3
284	Neutrophil Extracellular Traps and Macrophage Extracellular Traps Predict Postoperative Recurrence in Resectable Nonfunctional Pancreatic Neuroendocrine Tumors. <i>Frontiers in Immunology</i> , 2021 , 12, 577517	8.4	5
283	Neutrophil extracellular DNA traps promote pancreatic cancer cells migration and invasion by activating EGFR/ERK pathway. <i>Journal of Cellular and Molecular Medicine</i> , 2021 , 25, 5443-5456	5.6	15
282	Role of Somatostatin Receptor in Pancreatic Neuroendocrine Tumor Development, Diagnosis, and Therapy. <i>Frontiers in Endocrinology</i> , 2021 , 12, 679000	5.7	4
281	A Novel Validated Recurrence Stratification System Based on F-FDG PET/CT Radiomics to Guide Surveillance After Resection of Pancreatic Cancer. <i>Frontiers in Oncology</i> , 2021 , 11, 650266	5.3	1
280	Head-to-head comparison between FOLFIRINOX and gemcitabine plus nab-paclitaxel in the neoadjuvant chemotherapy of localized pancreatic cancer: a systematic review and meta-analysis. <i>Gland Surgery</i> , 2021 , 10, 1564-1575	2.2	3
279	Guidelines for the diagnosis and treatment of pancreatic cancer in China (2021). <i>Journal of Pancreatology</i> , 2021 , 4, 49-66	1.9	2
278	Applications of single-cell sequencing in cancer research: progress and perspectives. <i>Journal of Hematology and Oncology</i> , 2021 , 14, 91	22.4	17
277	Prognostic Significance of Altered ATRX/DAXX Gene in Pancreatic Neuroendocrine Tumors: A Meta-Analysis. <i>Frontiers in Endocrinology</i> , 2021 , 12, 691557	5.7	2
276	Overcoming chemoresistance by targeting reprogrammed metabolism: the AchillesHeel of pancreatic ductal adenocarcinoma. <i>Cellular and Molecular Life Sciences</i> , 2021 , 78, 5505-5526	10.3	5
275	FGFBP1-mediated crosstalk between fibroblasts and pancreatic cancer cells via FGF22/FGFR2 promotes invasion and metastasis of pancreatic cancer. <i>Acta Biochimica Et Biophysica Sinica</i> , 2021 , 53, 997-1008	2.8	1
274	Clinicopathological characteristics and prognosis of 232 patients with poorly differentiated gastric neuroendocrine neoplasms. <i>World Journal of Gastroenterology</i> , 2021 , 27, 2895-2909	5.6	1

273	Follicular Helper T Cells Remodel the Immune Microenvironment of Pancreatic Cancer via Secreting CXCL13 and IL-21. <i>Cancers</i> , 2021 , 13,	6.6	7
272	Analysis of Immune-Related Signatures Related to CD4+ T Cell Infiltration With Gene Co-Expression Network in Pancreatic Adenocarcinoma. <i>Frontiers in Oncology</i> , 2021 , 11, 674897	5.3	0
271	Bidirectional and dynamic interaction between the microbiota and therapeutic resistance in pancreatic cancer. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2021 , 1875, 188484	11.2	3
270	FBW7-NRA41-SCD1 axis synchronously regulates apoptosis and ferroptosis in pancreatic cancer cells. <i>Redox Biology</i> , 2021 , 38, 101807	11.3	35
269	Human splenic TER cells: A relevant prognostic factor acting via the artemin-GFRβ-ERK pathway in pancreatic ductal adenocarcinoma. <i>International Journal of Cancer</i> , 2021 , 148, 1756-1767	7.5	5
268	SETD8 potentiates constitutive ERK1/2 activation via epigenetically silencing DUSP10 expression in pancreatic cancer. <i>Cancer Letters</i> , 2021 , 499, 265-278	9.9	6
267	High pre-operative fasting blood glucose levels predict a poor prognosis in patients with pancreatic neuroendocrine tumour. <i>Endocrine</i> , 2021 , 71, 494-501	4	2
266	Roles of CA19-9 in pancreatic cancer: Biomarker, predictor and promoter. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2021 , 1875, 188409	11.2	26
265	Development and Validation of a New Nomogram for Predicting Clinically Relevant Postoperative Pancreatic Fistula After Pancreatoduodenectomy. <i>World Journal of Surgery</i> , 2021 , 45, 261-269	3.3	4
264	The superiority of [Ga]-FAPI-04 over [F]-FDG PET/CT in imaging metastatic esophageal squamous cell carcinoma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021 , 48, 1248-1249	8.8	7
263	Construction of a novel risk model based on the random forest algorithm to distinguish pancreatic cancers with different prognoses and immune microenvironment features. <i>Bioengineered</i> , 2021 , 12, 3593-3602 ³	5.7	3
262	Microorganisms in chemotherapy for pancreatic cancer: An overview of current research and future directions. <i>International Journal of Biological Sciences</i> , 2021 , 17, 2666-2682	11.2	2
261	The clinical characteristics and survival associations of pancreatic neuroendocrine tumors: does age matter?. <i>Gland Surgery</i> , 2021 , 10, 574-583	2.2	0
260	Body Composition and Response and Outcome of Neoadjuvant Treatment for Pancreatic Cancer. <i>Nutrition and Cancer</i> , 2021 , 1-10	2.8	1
259	Hyperdense Pancreatic Ductal Adenocarcinoma: Clinical Characteristics and Proteomic Landscape. <i>Frontiers in Oncology</i> , 2021 , 11, 640820	5.3	0
258	Mutations in key driver genes of pancreatic cancer: molecularly targeted therapies and other clinical implications. <i>Acta Pharmacologica Sinica</i> , 2021 , 42, 1725-1741	8	6
257	A novel risk factor panel predicts early recurrence in resected pancreatic neuroendocrine tumors. <i>Journal of Gastroenterology</i> , 2021 , 56, 395-405	6.9	5
256	Predictive Values of Preoperative Markers for Resectable Pancreatic Body and Tail Cancer Determined by MDCT to Detect Occult Metastases. <i>World Journal of Surgery</i> , 2021 , 45, 2185-2190	3.3	1

255	Tumour-derived exosomal lncRNA-SOX2OT promotes bone metastasis of non-small cell lung cancer by targeting the miRNA-194-5p/RAC1 signalling axis in osteoclasts. <i>Cell Death and Disease</i> , 2021 , 12, 662	9.8	8
254	MTAP Deficiency-Induced Metabolic Reprogramming Creates a Vulnerability to Cotargeting Purine Synthesis and Glycolysis in Pancreatic Cancer. <i>Cancer Research</i> , 2021 , 81, 4964-4980	10.1	2
253	Circular RNA CircEYA3 induces energy production to promote pancreatic ductal adenocarcinoma progression through the miR-1294/c-Myc axis. <i>Molecular Cancer</i> , 2021 , 20, 106	42.1	12
252	Improved tumor control with antiangiogenic therapy after treatment with gemcitabine and nab-paclitaxel in pancreatic cancer. <i>Clinical and Translational Medicine</i> , 2021 , 11, e398	5.7	
251	ALDOA inhibits cell cycle arrest induced by DNA damage via the ATM-PLK1 pathway in pancreatic cancer cells. <i>Cancer Cell International</i> , 2021 , 21, 514	6.4	1
250	Ferroptosis-related lncRNA pairs to predict the clinical outcome and molecular characteristics of pancreatic ductal adenocarcinoma. <i>Briefings in Bioinformatics</i> , 2021 ,	13.4	4
249	Fibrinogen/Albumin Ratio as a Promising Marker for Predicting Survival in Pancreatic Neuroendocrine Neoplasms. <i>Cancer Management and Research</i> , 2021 , 13, 107-115	3.6	5
248	Circular RNA in pancreatic cancer: a novel avenue for the roles of diagnosis and treatment. <i>Theranostics</i> , 2021 , 11, 2755-2769	12.1	18
247	SETD8 induces stemness and epithelial-mesenchymal transition of pancreatic cancer cells by regulating ROR1 expression. <i>Acta Biochimica Et Biophysica Sinica</i> , 2021 , 53, 1614-1624	2.8	1
246	High GFPT1 expression predicts unfavorable outcomes in patients with resectable pancreatic ductal adenocarcinoma. <i>World Journal of Surgical Oncology</i> , 2021 , 19, 35	3.4	1
245	Lipid raft involvement in signal transduction in cancer cell survival, cell death and metastasis.. <i>Cell Proliferation</i> , 2021 , e13167	7.9	3
244	The role of ferroptosis regulators in the prognosis, immune activity and gemcitabine resistance of pancreatic cancer. <i>Annals of Translational Medicine</i> , 2020 , 8, 1347	3.2	30
243	Advances on diagnostic biomarkers of pancreatic ductal adenocarcinoma: A systems biology perspective. <i>Computational and Structural Biotechnology Journal</i> , 2020 , 18, 3606-3614	6.8	5
242	Killing the "BAD": Challenges for immunotherapy in pancreatic cancer. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2020 , 1874, 188384	11.2	6
241	Neoadjuvant Treatment for Pancreatic Cancer: Still a Controversial Issue?. <i>Journal of Clinical Oncology</i> , 2020 , 38, 2943-2944	2.2	1
240	Differentiation of solid-pseudopapillary tumors of the pancreas from pancreatic neuroendocrine tumors by using endoscopic ultrasound. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2020 , 44, 947-953	2.4	6
239	Prognostic Value of the C-Reactive Protein/Lymphocyte Ratio in Pancreatic Cancer. <i>Annals of Surgical Oncology</i> , 2020 , 27, 4017-4025	3.1	13
238	PARP inhibitors in pancreatic cancer: molecular mechanisms and clinical applications. <i>Molecular Cancer</i> , 2020 , 19, 49	42.1	69

237	Prior history of acute pancreatitis predicts poor survival in patients with resectable pancreatic ductal adenocarcinoma. <i>Pancreatology</i> , 2020 , 20, 716-721	3.8	1
236	Ferroptosis: Final destination for cancer?. <i>Cell Proliferation</i> , 2020 , 53, e12761	7.9	30
235	HNF-1a promotes pancreatic cancer growth and apoptosis resistance via its target gene PKLR. <i>Acta Biochimica Et Biophysica Sinica</i> , 2020 , 52, 241-250	2.8	3
234	Kras mutation correlating with circulating regulatory T cells predicts the prognosis of advanced pancreatic cancer patients. <i>Cancer Medicine</i> , 2020 , 9, 2153-2159	4.8	14
233	Pin1 promotes pancreatic cancer progression and metastasis by activation of NF- κ B-IL-18 feedback loop. <i>Cell Proliferation</i> , 2020 , 53, e12816	7.9	11
232	Resected Pancreatic Cancer With N2 Node Involvement Is Refractory to Gemcitabine-Based Adjuvant Chemotherapy. <i>Cancer Control</i> , 2020 , 27, 1073274820915947	2.2	0
231	The value of a metabolic reprogramming-related gene signature for pancreatic adenocarcinoma prognosis prediction. <i>Aging</i> , 2020 , 12, 24228-24241	5.6	6
230	Prognostic value of circulating tumor DNA in pancreatic cancer: a systematic review and meta-analysis. <i>Aging</i> , 2020 , 13, 2031-2048	5.6	3
229	Active surveillance in metastatic pancreatic neuroendocrine tumors: A 20-year single-institutional experience. <i>World Journal of Clinical Cases</i> , 2020 , 8, 3751-3762	1.6	
228	Antitumor Effect of Cycle Inhibiting Factor Expression in Colon Cancer VNP20009. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2020 , 20, 1722-1727	2.2	1
227	Abrogation of ARF6 promotes RSL3-induced ferroptosis and mitigates gemcitabine resistance in pancreatic cancer cells. <i>American Journal of Cancer Research</i> , 2020 , 10, 1182-1193	4.4	15
226	Haemoglobin, albumin, lymphocyte and platelet predicts postoperative survival in pancreatic cancer. <i>World Journal of Gastroenterology</i> , 2020 , 26, 828-838	5.6	21
225	Clinical implication of serum CA125 for the prediction of malignancy in mucinous cystic neoplasms of the pancreas. <i>Experimental and Therapeutic Medicine</i> , 2020 , 20, 158	2.1	1
224	Lewis antigen-negative pancreatic cancer: An aggressive subgroup. <i>International Journal of Oncology</i> , 2020 , 56, 900-908	4.4	6
223	The role of m6A-related genes in the prognosis and immune microenvironment of pancreatic adenocarcinoma. <i>PeerJ</i> , 2020 , 8, e9602	3.1	26
222	Prognosis of distal pancreatic cancers controlled by stage. <i>Experimental and Therapeutic Medicine</i> , 2020 , 20, 1091-1097	2.1	0
221	Function and regulation of F-box/WD repeat-containing protein 7. <i>Oncology Letters</i> , 2020 , 20, 1526-1534	4.6	1
220	Expression Patterns and Prognostic Value of DNA Damage Repair Proteins in Resected Pancreatic Neuroendocrine Neoplasms. <i>Annals of Surgery</i> , 2020 , 275,	7.8	2

219	Hypoxia: a barricade to conquer the pancreatic cancer. <i>Cellular and Molecular Life Sciences</i> , 2020 , 77, 3077-3083	10.3	23
218	Clinical and Prognostic Implications of (WAF1/CIP1) Expression in Patients with Esophageal Cancer: A Systematic Review and Meta-Analysis. <i>Disease Markers</i> , 2020 , 2020, 6520259	3.2	4
217	Prognostic Value of Pancreatic Fistula in Resected Patients With Pancreatic Cancer With Neoadjuvant Therapy. <i>JAMA Surgery</i> , 2020 , 155, 267-268	5.4	
216	AJCC 8th edition staging system for pancreatic ductal adenocarcinoma: A controversial step forward?. <i>European Journal of Surgical Oncology</i> , 2020 , 46, 703	3.6	1
215	Molecular alterations and targeted therapy in pancreatic ductal adenocarcinoma. <i>Journal of Hematology and Oncology</i> , 2020 , 13, 130	22.4	42
214	Infiltrating pattern and prognostic value of tertiary lymphoid structures in resected non-functional pancreatic neuroendocrine tumors 2020 , 8,		5
213	Precise and efficient silencing of mutant Kras by CRISPR-CasRx controls pancreatic cancer progression. <i>Theranostics</i> , 2020 , 10, 11507-11519	12.1	9
212	Cancer-associated fibroblasts in therapeutic resistance of pancreatic cancer: Present situation, predicaments, and perspectives. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2020 , 1874, 188444	11.2	6
211	Risk factors of postoperative recurrence and potential candidate of adjuvant radiotherapy in lung adenocarcinoma. <i>Journal of Thoracic Disease</i> , 2020 , 12, 5593-5602	2.6	1
210	The promising role of noncoding RNAs in cancer-associated fibroblasts: an overview of current status and future perspectives. <i>Journal of Hematology and Oncology</i> , 2020 , 13, 154	22.4	8
209	Pancreatic total laparoscopic resection with preservation of the spleen for TIPMP (with video). <i>Journal De Chirurgie Viscérale</i> , 2020 , 157, 453-454	0	
208	TET1 downregulates epithelial-mesenchymal transition and chemoresistance in PDAC by demethylating CHL1 to inhibit the Hedgehog signaling pathway. <i>Oncogene</i> , 2020 , 39, 5825-5838	9.2	8
207	Classification of extrachromosomal circular DNA with a focus on the role of extrachromosomal DNA (ecDNA) in tumor heterogeneity and progression. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2020 , 1874, 188392	11.2	22
206	Absolute Counts of Peripheral Lymphocyte Subsets Correlate with the Progression-Free Survival and Metastatic Status of Pancreatic Neuroendocrine Tumour Patients. <i>Cancer Management and Research</i> , 2020 , 12, 6727-6737	3.6	2
205	Ferroptosis, necroptosis, and pyroptosis in anticancer immunity. <i>Journal of Hematology and Oncology</i> , 2020 , 13, 110	22.4	208
204	Tumor mutation burden in Chinese cancer patients and the underlying driving pathways of high tumor mutation burden across different cancer types. <i>Annals of Translational Medicine</i> , 2020 , 8, 860	3.2	4
203	Molecular drivers and cells of origin in pancreatic ductal adenocarcinoma and pancreatic neuroendocrine carcinoma. <i>Experimental Hematology and Oncology</i> , 2020 , 9, 28	7.8	6
202	Surufatinib in advanced pancreatic neuroendocrine tumours (SANET-p): a randomised, double-blind, placebo-controlled, phase 3 study. <i>Lancet Oncology</i> , 2020 , 21, 1489-1499	21.7	39

201	Surufatinib in advanced extrapancreatic neuroendocrine tumours (SANET-ep): a randomised, double-blind, placebo-controlled, phase 3 study. <i>Lancet Oncology, The</i> , 2020 , 21, 1500-1512	21.7	38
200	International expert consensus on laparoscopic pancreaticoduodenectomy. <i>Hepatobiliary Surgery and Nutrition</i> , 2020 , 9, 464-483	2.1	12
199	Supraclavicular Recurrence in Completely Resected (y)pN2 Non-Small Cell Lung Cancer: Implications for Postoperative Radiotherapy. <i>Frontiers in Oncology</i> , 2020 , 10, 1414	5.3	1
198	Oncogenic function of TRIM2 in pancreatic cancer by activating ROS-related NRF2/ITGB7/FAK axis. <i>Oncogene</i> , 2020 , 39, 6572-6588	9.2	4
197	Regulation of metabolic reprogramming by tumor suppressor genes in pancreatic cancer. <i>Experimental Hematology and Oncology</i> , 2020 , 9,	7.8	2
196	The Strain Ratio as Obtained by Endoscopic Ultrasonography Elastography Correlates With the Stroma Proportion and the Prognosis of Local Pancreatic Cancer. <i>Annals of Surgery</i> , 2020 , 271, 559-565	7.8	13
195	TGFB1-induced autophagy affects the pattern of pancreatic cancer progression in distinct ways depending on SMAD4 status. <i>Autophagy</i> , 2020 , 16, 486-500	10.2	32
194	Localisation of PGK1 determines metabolic phenotype to balance metastasis and proliferation in patients with SMAD4-negative pancreatic cancer. <i>Gut</i> , 2020 , 69, 888-900	19.2	44
193	Tumor-Infiltrating Neutrophils Predict Poor Survival of Non-Functional Pancreatic Neuroendocrine Tumor. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020 , 105,	5.6	7
192	ASO Author Reflections: C-Reactive Protein/Lymphocyte Ratio as a Promising Marker for Predicting Survival in Pancreatic Cancer. <i>Annals of Surgical Oncology</i> , 2020 , 27, 4026-4027	3.1	2
191	A miR-146a-5p/TRAF6/NF-kB p65 axis regulates pancreatic cancer chemoresistance: functional validation and clinical significance. <i>Theranostics</i> , 2020 , 10, 3967-3979	12.1	49
190	Oncologic outcomes of minimally invasive versus open distal pancreatectomy for pancreatic neuroendocrine tumors: Randomized controlled trials are needed. <i>Journal of Surgical Oncology</i> , 2019 , 120, 1284-1285	2.8	1
189	The tumor immune microenvironment in gastroenteropancreatic neuroendocrine neoplasms. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2019 , 1872, 188311	11.2	15
188	A PD-L2-based immune marker signature helps to predict survival in resected pancreatic ductal adenocarcinoma 2019 , 7, 233		14
187	The role of collagen in cancer: from bench to bedside. <i>Journal of Translational Medicine</i> , 2019 , 17, 309	8.5	196
186	Kras mutation contributes to regulatory T cell conversion through activation of the MEK/ERK pathway in pancreatic cancer. <i>Cancer Letters</i> , 2019 , 446, 103-111	9.9	32
185	Determining the optimal number of examined lymph nodes for accurate staging of pancreatic cancer: An analysis using the nodal staging score model. <i>European Journal of Surgical Oncology</i> , 2019 , 45, 1069-1076	3.6	9
184	The role of necroptosis in cancer biology and therapy. <i>Molecular Cancer</i> , 2019 , 18, 100	42.1	206

183	The systemic inflammation response index predicts survival and recurrence in patients with resectable pancreatic ductal adenocarcinoma. <i>Cancer Management and Research</i> , 2019 , 11, 3327-3337	3.6	11
182	The microbiota and microbiome in pancreatic cancer: more influential than expected. <i>Molecular Cancer</i> , 2019 , 18, 97	42.1	88
181	Laparoscopic pancreaticoduodenectomy: are the best times coming?. <i>World Journal of Surgical Oncology</i> , 2019 , 17, 81	3.4	12
180	Codelivery Nanosystem Targeting the Deep Microenvironment of Pancreatic Cancer. <i>Nano Letters</i> , 2019 , 19, 3527-3534	11.5	35
179	UHRF1 promotes aerobic glycolysis and proliferation via suppression of SIRT4 in pancreatic cancer. <i>Cancer Letters</i> , 2019 , 452, 226-236	9.9	42
178	Distinct clinicopathological and prognostic features of insulinoma with synchronous distant metastasis. <i>Pancreatology</i> , 2019 , 19, 472-477	3.8	5
177	Role of hepatocyte nuclear factor 4 alpha in cell proliferation and gemcitabine resistance in pancreatic adenocarcinoma. <i>Cancer Cell International</i> , 2019 , 19, 49	6.4	11
176	PRMT5 enhances tumorigenicity and glycolysis in pancreatic cancer via the FBW7/cMyc axis. <i>Cell Communication and Signaling</i> , 2019 , 17, 30	7.5	44
175	Surgical Resection for Metastatic Tumors in the Pancreas: A Single-Center Experience and Systematic Review. <i>Annals of Surgical Oncology</i> , 2019 , 26, 1649-1656	3.1	10
174	Homeodomain-interacting protein kinase 2 suppresses proliferation and aerobic glycolysis via ERK/cMyc axis in pancreatic cancer. <i>Cell Proliferation</i> , 2019 , 52, e12603	7.9	14
173	ASO Author Reflections: Tumor-Infiltrating NETs are New Biomarkers to Predict Postsurgical Survival for Patients with Pancreatic Ductal Adenocarcinoma. <i>Annals of Surgical Oncology</i> , 2019 , 26, 571-572	3.1	3
172	Reflections on depletion of tumor stroma in pancreatic cancer. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2019 , 1871, 267-272	11.2	12
171	AJCC 7th edition staging classification is more applicable than AJCC 8th edition staging classification for invasive IPMN. <i>World Journal of Surgical Oncology</i> , 2019 , 17, 137	3.4	4
170	Nab-paclitaxel plus gemcitabine as first-line treatment for advanced pancreatic cancer: a systematic review and meta-analysis. <i>Journal of Cancer</i> , 2019 , 10, 4420-4429	4.5	11
169	The Loss of Expression Associated with a Strongly Activated Hedgehog Signaling Pathway Predicts Poor Prognosis in Resected Pancreatic Cancer. <i>Journal of Cancer</i> , 2019 , 10, 4123-4131	4.5	9
168	Hexokinase 2 dimerization and interaction with voltage-dependent anion channel promoted resistance to cell apoptosis induced by gemcitabine in pancreatic cancer. <i>Cancer Medicine</i> , 2019 , 8, 5903-5915	4.8	20
167	ASO Author Reflections: Resection for Metastasis to the Pancreas-Worthwhile for Selected Patients. <i>Annals of Surgical Oncology</i> , 2019 , 26, 696-697	3.1	
166	Clinicopathological features and prognostic validity of the European Neuroendocrine Tumor Society (ENETS) and American Joint Committee on Cancer (AJCC) 8th staging systems in colonic neuroendocrine neoplasms. <i>Cancer Medicine</i> , 2019 , 8, 5000-5011	4.8	6

165	Research progress and design optimization of CAR-T therapy for pancreatic ductal adenocarcinoma. <i>Cancer Medicine</i> , 2019 , 8, 5223-5231	4.8	8
164	SRPX2 and RAB31 are effective prognostic biomarkers in pancreatic cancer. <i>Journal of Cancer</i> , 2019 , 10, 2670-2678	4.5	13
163	Management of solid pseudopapillary neoplasms of pancreas: A single center experience of 243 consecutive patients. <i>Pancreatology</i> , 2019 , 19, 681-685	3.8	21
162	Outcomes of Lymph Node Dissection for Nonmetastatic Pancreatic Neuroendocrine Tumors: To Dissect or Not To Dissect. <i>Annals of Surgical Oncology</i> , 2019 , 26, 872-873	3.1	
161	The impact of the nodal status and resection margin on the effectiveness of adjuvant chemotherapy for pancreatic cancer: It calls for more careful evaluation. <i>Journal of Surgical Oncology</i> , 2019 , 120, 1053-1054	2.8	
160	The CRP/Albumin Ratio Predicts Survival And Monitors Chemotherapeutic Effectiveness In Patients With Advanced Pancreatic Cancer. <i>Cancer Management and Research</i> , 2019 , 11, 8781-8788	3.6	8
159	Validation and head-to-head comparison of four models for predicting malignancy of intraductal papillary mucinous neoplasm of the pancreas: A study based on endoscopic ultrasound findings. <i>World Journal of Gastrointestinal Oncology</i> , 2019 , 11, 1043-1053	3.4	
158	FGFBP1, a downstream target of the FBW7/c-Myc axis, promotes cell proliferation and migration in pancreatic cancer. <i>American Journal of Cancer Research</i> , 2019 , 9, 2650-2664	4.4	10
157	Tumor-infiltrating platelets predict postoperative recurrence and survival in resectable pancreatic neuroendocrine tumor. <i>World Journal of Gastroenterology</i> , 2019 , 25, 6248-6257	5.6	13
156	Understanding genetic features of pancreatic neoplasm. <i>Chinese Clinical Oncology</i> , 2019 , 8, 15	2.3	
155	Tumor mutation burden analysis in a 5,660 cancer patient cohort reveals cancer type-specific mechanisms for high mutation burden.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 2589-2589	2.2	
154	Simultaneous resection of the primary tumour and liver metastases after conversion chemotherapy versus standard therapy in pancreatic cancer with liver oligometastasis: protocol of a multicentre, prospective, randomised phase III control trial (CSPAC-1). <i>BMJ Open</i> , 2019 , 9, e033452	3	7
153	Role of Damage DNA-Binding Protein 1 in Pancreatic Cancer Progression and Chemoresistance. <i>Cancers</i> , 2019 , 11,	6.6	5
152	Characteristics and Outcomes of Pancreatic Cancer by Histological Subtypes. <i>Pancreas</i> , 2019 , 48, 817-822.6		25
151	Prognostic and diagnostic significance of galectins in pancreatic cancer: a systematic review and meta-analysis. <i>Cancer Cell International</i> , 2019 , 19, 309	6.4	10
150	The reciprocal regulation between host tissue and immune cells in pancreatic ductal adenocarcinoma: new insights and therapeutic implications. <i>Molecular Cancer</i> , 2019 , 18, 184	42.1	29
149	The current surgical treatment of pancreatic cancer in China: a national wide cross-sectional study. <i>Journal of Pancreatology</i> , 2019 , 2, 16-21	1.9	13
148	Angiogenesis in pancreatic cancer: current research status and clinical implications. <i>Angiogenesis</i> , 2019 , 22, 15-36	10.6	94

147	Arpin downregulation is associated with poor prognosis in pancreatic ductal adenocarcinoma. <i>European Journal of Surgical Oncology</i> , 2019 , 45, 769-775	3.6	7
146	Selecting chemotherapy for pancreatic cancer: Far away or so close?. <i>Seminars in Oncology</i> , 2019 , 46, 39-47	5.5	8
145	Prognostic value of Eglutamytransferase-to-albumin ratio in patients with pancreatic ductal adenocarcinoma following radical surgery. <i>Cancer Medicine</i> , 2019 , 8, 572-584	4.8	11
144	PIN1 Maintains Redox Balance via the c-Myc/NRF2 Axis to Counteract Kras-Induced Mitochondrial Respiratory Injury in Pancreatic Cancer Cells. <i>Cancer Research</i> , 2019 , 79, 133-145	10.1	27
143	Tumor-Infiltrating NETs Predict Postsurgical Survival in Patients with Pancreatic Ductal Adenocarcinoma. <i>Annals of Surgical Oncology</i> , 2019 , 26, 635-643	3.1	45
142	Proposed Modification of the 8th Edition of the AJCC Staging System for Pancreatic Ductal Adenocarcinoma. <i>Annals of Surgery</i> , 2019 , 269, 944-950	7.8	41
141	TCF7L2 positively regulates aerobic glycolysis via the EGLN2/HIF-1 α axis and indicates prognosis in pancreatic cancer. <i>Cell Death and Disease</i> , 2018 , 9, 321	9.8	23
140	Strategies for pancreatic anastomosis after pancreaticoduodenectomy: What really matters?. <i>Hepatobiliary and Pancreatic Diseases International</i> , 2018 , 17, 22-26	2.1	12
139	MUC16 C terminal-induced secretion of tumor-derived IL-6 contributes to tumor-associated Treg enrichment in pancreatic cancer. <i>Cancer Letters</i> , 2018 , 418, 167-175	9.9	32
138	High throughput gene sequencing reveals altered landscape in DNA damage responses and chromatin remodeling in sporadic pancreatic neuroendocrine tumors. <i>Pancreatology</i> , 2018 , 18, 318-327	3.8	8
137	Mismatch repair status as a beneficial predictor of fluorouracil-based adjuvant chemotherapy for pancreatic cancer. <i>Surgery</i> , 2018 , 163, 1080-1089	3.6	3
136	dCK negatively regulates the NRF2/ARE axis and ROS production in pancreatic cancer. <i>Cell Proliferation</i> , 2018 , 51, e12456	7.9	14
135	The clinicopathological and prognostic significance of PD-L1 expression in pancreatic cancer: A meta-analysis. <i>Hepatobiliary and Pancreatic Diseases International</i> , 2018 , 17, 95-100	2.1	37
134	A novel scoring system predicts postsurgical survival and adjuvant chemotherapeutic benefits in patients with pancreatic adenocarcinoma: Implications for AJCC-TNM staging. <i>Surgery</i> , 2018 , 163, 1280-1294	3.6	15
133	RIPK4/PEBP1 axis promotes pancreatic cancer cell migration and invasion by activating RAF1/MEK/ERK signaling. <i>International Journal of Oncology</i> , 2018 , 52, 1105-1116	4.4	17
132	Novel recurrence risk stratification of resected pancreatic neuroendocrine tumor. <i>Cancer Letters</i> , 2018 , 412, 188-193	9.9	32
131	Do anti-stroma therapies improve extrinsic resistance to increase the efficacy of gemcitabine in pancreatic cancer?. <i>Cellular and Molecular Life Sciences</i> , 2018 , 75, 1001-1012	10.3	24
130	Clinicopathological features and outcome for neuroendocrine neoplasms of gastroesophageal junction: A population-based study. <i>Cancer Medicine</i> , 2018 , 7, 4361-4370	4.8	8

129	Postoperative serum CA19-9, CEA and CA125 predicts the response to adjuvant chemoradiotherapy following radical resection in pancreatic adenocarcinoma. <i>Pancreatology</i> , 2018 , 18, 671-677	3.8	13
128	Abrogation of glutathione peroxidase-1 drives EMT and chemoresistance in pancreatic cancer by activating ROS-mediated Akt/GSK3 β /Snail signaling. <i>Oncogene</i> , 2018 , 37, 5843-5857	9.2	62
127	Efficacy and Safety of Sunitinib in Patients with Well-Differentiated Pancreatic Neuroendocrine Tumours. <i>Neuroendocrinology</i> , 2018 , 107, 237-245	5.6	32
126	Upregulation of the Long Noncoding RNA SNHG3 Promotes Lung Adenocarcinoma Proliferation. <i>Disease Markers</i> , 2018 , 2018, 5736716	3.2	33
125	Novel agents for pancreatic ductal adenocarcinoma: emerging therapeutics and future directions. <i>Journal of Hematology and Oncology</i> , 2018 , 11, 14	22.4	22
124	New observations on the utility of CA19-9 as a biomarker in Lewis negative patients with pancreatic cancer. <i>Pancreatology</i> , 2018 , 18, 971-976	3.8	19
123	Application of the Eighth Edition of the American Joint Committee on Cancer Staging for Pancreatic Adenocarcinoma. <i>Pancreas</i> , 2018 , 47, 742-747	2.6	12
122	A robust gene expression-based prognostic risk score predicts overall survival of lung adenocarcinoma patients. <i>Oncotarget</i> , 2018 , 9, 6862-6871	3.3	6
121	Circulating biomarkers for early diagnosis of pancreatic cancer: facts and hopes. <i>American Journal of Cancer Research</i> , 2018 , 8, 332-353	4.4	23
120	Zinc finger E-box-binding homeobox 1 mediates aerobic glycolysis suppression of sirtuin 3 in pancreatic cancer. <i>World Journal of Gastroenterology</i> , 2018 , 24, 4893-4905	5.6	10
119	Intrinsic Contact Between T and N Classifications in Resected Well-Moderately Differentiated Locoregional Pancreatic Neuroendocrine Neoplasms. <i>Annals of Surgical Oncology</i> , 2018 , 25, 647-654	3.1	6
118	The impact of cancer-associated fibroblasts on major hallmarks of pancreatic cancer. <i>Theranostics</i> , 2018 , 8, 5072-5087	12.1	91
117	GPx1 is involved in the induction of protective autophagy in pancreatic cancer cells in response to glucose deprivation. <i>Cell Death and Disease</i> , 2018 , 9, 1187	9.8	20
116	The Significance of Liquid Biopsy in Pancreatic Cancer. <i>Journal of Cancer</i> , 2018 , 9, 3417-3426	4.5	28
115	Role of angiogenesis in pancreatic cancer biology and therapy. <i>Biomedicine and Pharmacotherapy</i> , 2018 , 108, 1135-1140	7.5	29
114	ASO Author Reflections: Contact Between T and N Classifications in Pancreatic Neuroendocrine Neoplasms. <i>Annals of Surgical Oncology</i> , 2018 , 25, 814-815	3.1	
113	ASO Author Reflections: Tumor-Infiltrating Platelets Predict Postsurgical Survival in Patients with Pancreatic Ductal Adenocarcinoma. <i>Annals of Surgical Oncology</i> , 2018 , 25, 3994-3995	3.1	0
112	Tumor-Infiltrating Platelets Predict Postsurgical Survival in Patients with Pancreatic Ductal Adenocarcinoma. <i>Annals of Surgical Oncology</i> , 2018 , 25, 3984-3993	3.1	13

111	Current status and dilemma of second-line treatment in advanced pancreatic cancer: is there a silver lining?. <i>OncoTargets and Therapy</i> , 2018 , 11, 4591-4608	4.4	3
110	Anergic natural killer cells educated by tumor cells are associated with a poor prognosis in patients with advanced pancreatic ductal adenocarcinoma. <i>Cancer Immunology, Immunotherapy</i> , 2018 , 67, 1815-1823	7.4	10
109	MiR-29a, targeting caveolin 2 expression, is responsible for limitation of pancreatic cancer metastasis in patients with normal level of serum CA125. <i>International Journal of Cancer</i> , 2018 , 143, 2919-2931	7.5	19
108	Clinical application of Tc-HYNIC-TOC SPECT/CT in diagnosing and monitoring of pancreatic neuroendocrine neoplasms. <i>Annals of Nuclear Medicine</i> , 2018 , 32, 446-452	2.5	4
107	Potential Biomarkers in Lewis Negative Patients With Pancreatic Cancer. <i>Annals of Surgery</i> , 2017 , 265, 800-805	7.8	75
106	Patients with normal-range CA19-9 levels represent a distinct subgroup of pancreatic cancer patients. <i>Oncology Letters</i> , 2017 , 13, 881-886	2.6	4
105	Oncogenic KRAS Targets MUC16/CA125 in Pancreatic Ductal Adenocarcinoma. <i>Molecular Cancer Research</i> , 2017 , 15, 201-212	6.6	32
104	Analysis of ctDNA to predict prognosis and monitor treatment responses in metastatic pancreatic cancer patients. <i>International Journal of Cancer</i> , 2017 , 140, 2344-2350	7.5	88
103	Surgery management for sporadic small (≤ 2 cm), non-functioning pancreatic neuroendocrine tumors: a consensus statement by the Chinese Study Group for Neuroendocrine Tumors (CSNET). <i>International Journal of Oncology</i> , 2017 , 50, 567-574	4.4	23
102	A new facet of NDRG1 in pancreatic ductal adenocarcinoma: Suppression of glycolytic metabolism. <i>International Journal of Oncology</i> , 2017 , 50, 1792-1800	4.4	13
101	Clinical outcomes and prognostic factors of resected pancreatic neuroendocrine neoplasms: A single-center experience in China. <i>Oncology Letters</i> , 2017 , 13, 3163-3168	2.6	9
100	Somatostatin receptor expression indicates improved prognosis in gastroenteropancreatic neuroendocrine neoplasm, and octreotide long-acting release is effective and safe in Chinese patients with advanced gastroenteropancreatic neuroendocrine tumors. <i>Oncology Letters</i> , 2017 , 13, 1165-1171	2.6	36
99	Neutrophil-lymphocyte ratio predicts survival in pancreatic neuroendocrine tumors. <i>Oncology Letters</i> , 2017 , 13, 2454-2458	2.6	21
98	Revised nodal stage for pancreatic neuroendocrine tumors. <i>Pancreatology</i> , 2017 , 17, 599-604	3.8	9
97	ARF6, induced by mutant Kras, promotes proliferation and Warburg effect in pancreatic cancer. <i>Cancer Letters</i> , 2017 , 388, 303-311	9.9	27
96	Carbohydrate antigen 19-9 as a prognostic biomarker in pancreatic neuroendocrine tumors. <i>Oncology Letters</i> , 2017 , 14, 6795-6800	2.6	14
95	FBW7 increases the chemosensitivity of pancreatic cancer cells to gemcitabine through upregulation of ENT1. <i>Oncology Reports</i> , 2017 , 38, 2069-2077	3.5	19
94	Diagnostic Accuracy of a CA125-Based Biomarker Panel in Patients with Pancreatic Cancer: A Systematic Review and Meta-Analysis. <i>Journal of Cancer</i> , 2017 , 8, 3615-3622	4.5	8

93	Clinicopathological features and prognostic validity of WHO grading classification of SI-NENs. <i>BMC Cancer</i> , 2017 , 17, 521	4.8	8
92	Human profilin 1 is a negative regulator of CTL mediated cell-killing and migration. <i>European Journal of Immunology</i> , 2017 , 47, 1562-1572	6.1	25
91	Complex roles of the stroma in the intrinsic resistance to gemcitabine in pancreatic cancer: where we are and where we are going. <i>Experimental and Molecular Medicine</i> , 2017 , 49, e406	12.8	75
90	Sunitinib is effective and tolerable in Chinese patients with advanced pancreatic neuroendocrine tumors: a multicenter retrospective study in China. <i>Cancer Chemotherapy and Pharmacology</i> , 2017 , 80, 507-516	3.5	10
89	Postoperative serum CEA and CA125 levels are supplementary to perioperative CA19-9 levels in predicting operative outcomes of pancreatic ductal adenocarcinoma. <i>Surgery</i> , 2017 , 161, 373-384	3.6	33
88	CA19-9-Low&Lewis (+) pancreatic cancer: A unique subtype. <i>Cancer Letters</i> , 2017 , 385, 46-50	9.9	12
87	Prognostic Value of the CRP/Alb Ratio, a Novel Inflammation-Based Score in Pancreatic Cancer. <i>Annals of Surgical Oncology</i> , 2017 , 24, 561-568	3.1	90
86	Modified Staging Classification for Pancreatic Neuroendocrine Tumors on the Basis of the American Joint Committee on Cancer and European Neuroendocrine Tumor Society Systems. <i>Journal of Clinical Oncology</i> , 2017 , 35, 274-280	2.2	91
85	Diagnostic and prognostic value of carcinoembryonic antigen in pancreatic cancer: a systematic review and meta-analysis. <i>OncoTargets and Therapy</i> , 2017 , 10, 4591-4598	4.4	56
84	Somatic Genetic Variation in Solid Pseudopapillary Tumor of the Pancreas by Whole Exome Sequencing. <i>International Journal of Molecular Sciences</i> , 2017 , 18,	6.3	15
83	Circulating regulatory T cell subsets predict overall survival of patients with unresectable pancreatic cancer. <i>International Journal of Oncology</i> , 2017 , 51, 686-694	4.4	29
82	Toll-Like Receptor 4/MyD88-Mediated Signaling of Hepcidin Expression Causing Brain Iron Accumulation, Oxidative Injury, and Cognitive Impairment After Intracerebral Hemorrhage. <i>Circulation</i> , 2016 , 134, 1025-1038	16.7	75
81	Metabolic plasticity in heterogeneous pancreatic ductal adenocarcinoma. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2016 , 1866, 177-188	11.2	15
80	Surgical management for non-functional pancreatic neuroendocrine neoplasms with synchronous liver metastasis: A consensus from the Chinese Study Group for Neuroendocrine Tumors (CSNET). <i>International Journal of Oncology</i> , 2016 , 49, 1991-2000	4.4	15
79	Mutant p53 determines pancreatic cancer poor prognosis to pancreatectomy through upregulation of cavin-1 in patients with preoperative serum CA19-9 $\geq 1,000$ U/mL. <i>Scientific Reports</i> , 2016 , 6, 19222	4.9	22
78	Critical role of oncogenic KRAS in pancreatic cancer (Review). <i>Molecular Medicine Reports</i> , 2016 , 13, 4943-4949	2.9	23
77	New insights into perineural invasion of pancreatic cancer: More than pain. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2016 , 1865, 111-22	11.2	27
76	Roux-en-Y pancreaticojejunostomy reconstruction after deep enucleation of benign or borderline pancreatic lesions: a single-institution experience. <i>Hpb</i> , 2016 , 18, 145-152	3.8	5

75	FBW7 (F-box and WD Repeat Domain-Containing 7) Negatively Regulates Glucose Metabolism by Targeting the c-Myc/TXNIP (Thioredoxin-Binding Protein) Axis in Pancreatic Cancer. <i>Clinical Cancer Research</i> , 2016 , 22, 3950-60	12.9	60
74	The clinical utility of CA125/MUC16 in pancreatic cancer: A consensus of diagnostic, prognostic and predictive updates by the Chinese Study Group for Pancreatic Cancer (CSPAC). <i>International Journal of Oncology</i> , 2016 , 48, 900-7	4.4	12
73	ALDOA functions as an oncogene in the highly metastatic pancreatic cancer. <i>Cancer Letters</i> , 2016 , 374, 127-135	9.9	73
72	Which patients with para-aortic lymph node (LN16) metastasis will truly benefit from curative pancreaticoduodenectomy for pancreatic head cancer?. <i>Oncotarget</i> , 2016 , 7, 29177-86	3.3	8
71	Serum CA125 is a novel predictive marker for pancreatic cancer metastasis and correlates with the metastasis-associated burden. <i>Oncotarget</i> , 2016 , 7, 5943-56	3.3	46
70	The Prognostic and Predictive Role of Epidermal Growth Factor Receptor in Surgical Resected Pancreatic Cancer. <i>International Journal of Molecular Sciences</i> , 2016 , 17,	6.3	14
69	Retraction: Mutant p53 determines pancreatic cancer poor prognosis to pancreatectomy through upregulation of cavin-1 in patients with preoperative serum CA19-9 $\geq 1,000$ U/mL. <i>Scientific Reports</i> , 2016 , 6, 25115	4.9	6
68	Pancreatic cancer risk variant in LINC00673 creates a miR-1231 binding site and interferes with PTPN11 degradation. <i>Nature Genetics</i> , 2016 , 48, 747-57	36.3	187
67	Optimize CA19-9 in detecting pancreatic cancer by Lewis and Secretor genotyping. <i>Pancreatology</i> , 2016 , 16, 1057-1062	3.8	20
66	The combination of systemic inflammation-based marker NLR and circulating regulatory T cells predicts the prognosis of resectable pancreatic cancer patients. <i>Pancreatology</i> , 2016 , 16, 1080-1084	3.8	46
65	Energy sources identify metabolic phenotypes in pancreatic cancer. <i>Acta Biochimica Et Biophysica Sinica</i> , 2016 , 48, 969-979	2.8	17
64	Blood neutrophil-lymphocyte ratio predicts survival in patients with advanced pancreatic cancer treated with chemotherapy. <i>Annals of Surgical Oncology</i> , 2015 , 22, 670-6	3.1	108
63	Papillary-like main pancreatic duct invaginated pancreaticojejunostomy versus duct-to-mucosa pancreaticojejunostomy after pancreaticoduodenectomy: A prospective randomized trial. <i>Surgery</i> , 2015 , 158, 1211-8	3.6	13
62	Lymph node status predicts the benefit of adjuvant chemoradiotherapy for patients with resected pancreatic cancer. <i>Pancreatology</i> , 2015 , 15, 253-8	3.8	16
61	Metabolic tumor burden is associated with major oncogenomic alterations and serum tumor markers in patients with resected pancreatic cancer. <i>Cancer Letters</i> , 2015 , 360, 227-33	9.9	31
60	Pancreatic cancer: BRCA mutation and personalized treatment. <i>Expert Review of Anticancer Therapy</i> , 2015 , 15, 1223-31	3.5	28
59	A comprehensive comparison of clinicopathologic and imaging features of incidental/symptomatic non-functioning pancreatic neuroendocrine tumors: A retrospective study of a single center. <i>Pancreatology</i> , 2015 , 15, 519-524	3.8	4
58	ERK kinase phosphorylates and destabilizes the tumor suppressor FBW7 in pancreatic cancer. <i>Cell Research</i> , 2015 , 25, 561-73	24.7	88

57	Epithelial-mesenchymal transition in pancreatic cancer: Is it a clinically significant factor?. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2015 , 1855, 43-9	11.2	24
56	A preoperative serum signature of CEA+/CA125+/CA19-9 ≥ 1000 U/mL indicates poor outcome to pancreatectomy for pancreatic cancer. <i>International Journal of Cancer</i> , 2015 , 136, 2216-27	7.5	71
55	Preoperative serum CA125 levels predict the prognosis in hyperbilirubinemia patients with resectable pancreatic ductal adenocarcinoma. <i>Medicine (United States)</i> , 2015 , 94, e751	1.8	20
54	Noncoding RNAs as potential biomarkers to predict the outcome in pancreatic cancer. <i>Drug Design, Development and Therapy</i> , 2015 , 9, 1247-55	4.4	19
53	Should a standard lymphadenectomy during pancreatoduodenectomy exclude para-aortic lymph nodes for all cases of resectable pancreatic head cancer? A consensus statement by the Chinese Study Group for Pancreatic Cancer (CSPAC). <i>International Journal of Oncology</i> , 2015 , 47, 1512-6	4.4	7
52	Metabolic tumor burden: a new promising way to reach precise personalized therapy in PDAC. <i>Cancer Letters</i> , 2015 , 359, 165-8	9.9	11
51	MicroRNA-33a-mediated downregulation of Pim-3 kinase expression renders human pancreatic cancer cells sensitivity to gemcitabine. <i>Oncotarget</i> , 2015 , 6, 14440-55	3.3	49
50	Normalization of CA19-9 following resection for pancreatic ductal adenocarcinoma is not tantamount to being cured?. <i>Asian Pacific Journal of Cancer Prevention</i> , 2015 , 16, 661-6	1.7	
49	Metabolic tumour burden assessed by 18 F-FDG PET/CT associated with serum CA19-9 predicts pancreatic cancer outcome after resection. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2014 , 41, 1093-102	8.8	65
48	Cancer statistics: current diagnosis and treatment of pancreatic cancer in Shanghai, China. <i>Cancer Letters</i> , 2014 , 346, 273-7	9.9	92
47	Stathmin destabilizing microtubule dynamics promotes malignant potential in cancer cells by epithelial-mesenchymal transition. <i>Hepatobiliary and Pancreatic Diseases International</i> , 2014 , 13, 386-94	2.1	24
46	Abnormal distribution of peripheral lymphocyte subsets induced by PDAC modulates overall survival. <i>Pancreatology</i> , 2014 , 14, 295-301	3.8	28
45	Profilin-1 suppresses tumorigenicity in pancreatic cancer through regulation of the SIRT3-HIF1 α axis. <i>Molecular Cancer</i> , 2014 , 13, 187	42.1	36
44	(18 F)-FDG PET/CT can be used to detect non-functioning pancreatic neuroendocrine tumors. <i>International Journal of Oncology</i> , 2014 , 45, 1531-6	4.4	12
43	Effect of the number of positive lymph nodes and lymph node ratio on prognosis of patients after resection of pancreatic adenocarcinoma. <i>Hepatobiliary and Pancreatic Diseases International</i> , 2014 , 13, 634-41	2.1	18
42	A school-based study of irritable bowel syndrome in medical students in Beijing, China: prevalence and some related factors. <i>Gastroenterology Research and Practice</i> , 2014 , 2014, 124261	2	19
41	Molecular mechanism underlying lymphatic metastasis in pancreatic cancer. <i>BioMed Research International</i> , 2014 , 2014, 925845	3	19
40	Visceral and somatic hypersensitivity, autonomic cardiovascular dysfunction and low-grade inflammation in a subset of irritable bowel syndrome patients. <i>Journal of Zhejiang University: Science B</i> , 2014 , 15, 907-14	4.5	9

39	LSD1 sustains pancreatic cancer growth via maintaining HIF1 α -dependent glycolytic process. <i>Cancer Letters</i> , 2014 , 347, 225-32	9.9	48
38	The combination of HTATIP2 expression and microvessel density predicts converse survival of hepatocellular carcinoma with or without sorafenib. <i>Oncotarget</i> , 2014 , 5, 3895-906	3.3	16
37	Application of "papillary-like main pancreatic duct invaginated" pancreaticojejunostomy for normal soft pancreas cases. <i>Scientific Reports</i> , 2013 , 3, 2068	4.9	7
36	CA125 is superior to CA19-9 in predicting the resectability of pancreatic cancer. <i>Journal of Gastrointestinal Surgery</i> , 2013 , 17, 2092-8	3.3	51
35	A novel epigenetic CREB-miR-373 axis mediates ZIP4-induced pancreatic cancer growth. <i>EMBO Molecular Medicine</i> , 2013 , 5, 1322-34	12	69
34	Identification of common variants in BRCA2 and MAP2K4 for susceptibility to sporadic pancreatic cancer. <i>Carcinogenesis</i> , 2013 , 34, 1001-5	4.6	18
33	Silencing of MBD1 reverses pancreatic cancer therapy resistance through inhibition of DNA damage repair. <i>International Journal of Oncology</i> , 2013 , 42, 2046-52	4.4	22
32	Highly lymphatic metastatic pancreatic cancer cells possess stem cell-like properties. <i>International Journal of Oncology</i> , 2013 , 42, 979-84	4.4	29
31	A novel regulatory mechanism of Pim-3 kinase stability and its involvement in pancreatic cancer progression. <i>Molecular Cancer Research</i> , 2013 , 11, 1508-20	6.6	31
30	Role of SUV(max) obtained by 18F-FDG PET/CT in patients with a solitary pancreatic lesion: predicting malignant potential and proliferation. <i>Nuclear Medicine Communications</i> , 2013 , 34, 533-9	1.6	40
29	Intratumoral α 5 β 1 enhances the prognostic potency of CD34 associated with maintenance of microvessel integrity in hepatocellular carcinoma and pancreatic cancer. <i>PLoS ONE</i> , 2013 , 8, e71189	3.7	55
28	Significance of caveolin-1 regulators in pancreatic cancer. <i>Asian Pacific Journal of Cancer Prevention</i> , 2013 , 14, 4501-7	1.7	7
27	Stroma and pancreatic ductal adenocarcinoma: an interaction loop. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2012 , 1826, 170-8	11.2	16
26	Profilin1 facilitates staurosporine-triggered apoptosis by stabilizing the integrin β -actin complex in breast cancer cells. <i>Journal of Cellular and Molecular Medicine</i> , 2012 , 16, 824-35	5.6	19
25	Development of a unique mouse model for pancreatic cancer lymphatic metastasis. <i>International Journal of Oncology</i> , 2012 , 41, 1662-8	4.4	18
24	Pancreatic stump-closed pancreaticojejunostomy can be performed safely in normal soft pancreas cases. <i>Journal of Surgical Research</i> , 2012 , 172, e11-7	2.5	17
23	Combinational therapy: new hope for pancreatic cancer?. <i>Cancer Letters</i> , 2012 , 317, 127-35	9.9	70
22	Tanshinone IIA inhibits metastasis after palliative resection of hepatocellular carcinoma and prolongs survival in part via vascular normalization. <i>Journal of Hematology and Oncology</i> , 2012 , 5, 69	22.4	37

21	Quantum dots in cancer therapy. <i>Expert Opinion on Drug Delivery</i> , 2012 , 9, 47-58	8	32
20	RGD-conjugated albumin nanoparticles as a novel delivery vehicle in pancreatic cancer therapy. <i>Cancer Biology and Therapy</i> , 2012 , 13, 206-15	4.6	65
19	microRNA signature for human pancreatic cancer invasion and metastasis. <i>Experimental and Therapeutic Medicine</i> , 2012 , 4, 181-187	2.1	26
18	Management of a malignant case of solid pseudopapillary tumor of pancreas: a case report and literature review. <i>Pancreas</i> , 2012 , 41, 1336-40	2.6	22
17	Genome-wide association study identifies five loci associated with susceptibility to pancreatic cancer in Chinese populations. <i>Nature Genetics</i> , 2011 , 44, 62-6	36.3	141
16	Role of epidermal growth factor receptor expression on patient survival in pancreatic cancer: a meta-analysis. <i>Pancreatology</i> , 2011 , 11, 595-600	3.8	22
15	Overcoming drug resistance in pancreatic cancer. <i>Expert Opinion on Therapeutic Targets</i> , 2011 , 15, 817-28	6.4	157
14	A novel tripeptide, tyrosyleutide, inhibits irradiation-induced invasiveness and metastasis of hepatocellular carcinoma in nude mice. <i>Investigational New Drugs</i> , 2011 , 29, 861-72	4.3	20
13	A new approach to produce amino-carbon nanotubes as plasmid transfection vector by [2 + 1] cycloaddition of nitrenes. <i>Journal of Nanoparticle Research</i> , 2011 , 13, 33-38	2.3	6
12	High expression of macrophage colony-stimulating factor-1 receptor in peritumoral liver tissue is associated with poor outcome in hepatocellular carcinoma after curative resection. <i>Oncologist</i> , 2010 , 15, 732-43	5.7	46
11	Activation of beta-catenin by hypoxia in hepatocellular carcinoma contributes to enhanced metastatic potential and poor prognosis. <i>Clinical Cancer Research</i> , 2010 , 16, 2740-50	12.9	141
10	Developmental plasticity of stem cells and diseases. <i>Medical Hypotheses</i> , 2010 , 75, 507-10	3.8	5
9	LyP-1-conjugated nanoparticles for targeting drug delivery to lymphatic metastatic tumors. <i>International Journal of Pharmaceutics</i> , 2010 , 385, 150-6	6.5	121
8	Targeted drug delivery in pancreatic cancer. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2010 , 1805, 97-104	11.2	36
7	Carbon nanotubes in cancer diagnosis and therapy. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2010 , 1806, 29-35	11.2	130
6	Preparation of albumin nanospheres loaded with gemcitabine and their cytotoxicity against BXPC-3 cells in vitro. <i>Acta Pharmacologica Sinica</i> , 2009 , 30, 1337-43	8	50
5	Pilot study of targeting magnetic carbon nanotubes to lymph nodes. <i>Nanomedicine</i> , 2009 , 4, 317-30	5.6	48
4	Clinical experiences of solid pseudopapillary tumors of the pancreas in China. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2008 , 23, 1847-51	4	40

3	Proteomic analysis of differential proteins in pancreatic carcinomas: Effects of MBD1 knock-down by stable RNA interference. <i>BMC Cancer</i> , 2008 , 8, 121	4.8	14
2	Aberrant hepatic artery in patients undergoing pancreaticoduodenectomy. <i>Pancreatology</i> , 2008 , 8, 50-4	3.8	22
1	Analysis of gene expression profiles in pancreatic carcinoma by using cDNA microarray. <i>Hepatobiliary and Pancreatic Diseases International</i> , 2003 , 2, 467-70	2.1	10